Posts for Ticker ‘RHHBY’

Swine Flu Lessons from SARS, Mad Cow & Bird Flu of Past (GILD, BCRX, NVAX, GNBT, VICL, AVII, CRXL, RHHBY, GSK, SFD, EWW, MXF)

burning-money-pic27Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of the lessons of scares in the past of SARS, bird flu, Mad Cow, and even hoof & mouth as similar references.  The two approved drug treatments, not vaccines, which are being released are Tamiflu made by Roche (OTC: RHHBY) and Relenza made by GlaxoSmithkline (NYSE: GSK).  Gilead Sciences, Inc. (GILD) gets royalties from Roche for Tamiflu, and its shares are indicated north of $48.00 after a $45.80 close on Friday.  There are also waves of tier-two and tier-three stocks which could move on this news, but be advised that we have seen these pops in the past from SARS and Bird Flu which were followed ultimately by lower share prices and many of the speculative players disappeared.

Of the tier-two stocks, you have BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) and Novavax, Inc. (NASDAQ: NVAX).  Of the tier-three stocks you have Generex Biotechnology Corp. (NASDAQ: GNBT), Vical Inc. (NASDAQ: VICL), AVI Biopharma, Inc. (NASDAQ: AVII), and Crucell NV (NASDAQ: CRXL).  More descriptive data has been provided for each move.   On another scale, Smithfield Foods Inc. (NYSE: SFD), the iShares MSCI Mexico Investable Market Index (NYSE: EWW), and The Mexico Fund, Inc. (NYSE: MXF) have exposure here as well.
Read More »

Posted on: April 27, 2009 – 6:40 am in Biotech, Drug companies, Food, Medical, Pharmaceuticals, Regulation, Research, Trading Alert, , , , , , , , ,

Government Releases Swine Flu Treatment Stockpiles (RHHBY, GSK)

You have probably heard more and more about the swine flu epidemic from Mexico spreading to the U.S., and a new media advisory is confirming that the drugs Tamiflu by Roche (OTC: RHHBY) and Relenza by GlaxoSmithkline (NYSE: GSK) are being released to combat the swine flu.  While there was no mention of how many doses of each drug were in the total stockpile of 50 million doses, Homeland Security Secretary Janet Napolitano said in a White House briefing that the government is releasing 25% of the 50 million stockpiled doses to treat the outbreak.
Read More »

Posted on: April 26, 2009 – 12:49 pm in Biotech, Drug companies, Medical, Pharmaceuticals, Politics, Regulation, ,

Foreign Brands Gone Missing For Investors (NYX, NDAQ, ADDDF, BAESY, AHBIF, LVMHF, NSRGY, NTDOY, RHHBY, LUKOY)

There has been an interesting trend in the globalization movement.  The U.S. has seen some major brands and major companies get acquired by foreign public companies, but suddenly U.S. investors have a very hard time in investing in those companies again.   The NYSE Euronext, Inc. (NYSE: NYX) and the NASDAQ OMX Group Inc. (NASDAQ: NDAQ) have an opportunity to recruit many of these foreign companies to take on full US listings (again for some of them).  We also have many products and goods produced by foreign companies which we in the U.S. consume.  Despite most of these companies being public, most U.S. investors cannot easily invest in many of these icons.  Most brokers do not even know how to trade them.  The Peter Lynch method suggests investing in what you know, yet that notion is not possible in many of these companies for most Americans.  This form of globalization may feel like isolation for investors who want to own a piece of their favorite brands.

Throughout this decade, it became commonplace for large companies to stop having full listings in the U.S.  One reason was over the disclosure and regulatory rules, while some reasoned that the cost of listing was of little to no benefit to the company.  Some of these are at least traded OTC or on the Pink Sheets.  That is good or at least a start.  Unfortunately, most Americans  do not know how to invest in these markets.  For that matter, most brokers do not either.  Here are just some of the companies which trade OTC or on the Pink Sheets:
Read More »

Posted on: April 17, 2009 – 11:14 am in ADR, Consumer Goods, IPOs, International Markets, OTC, , , , , , , , , ,

Pre-Market Stock News (July 20, 2007)

(ACOR) Acorda COO resigned to pursue other interests.
(AMD) Advanced Micro Devices traded up 4% after revenues were ahead of plan on processor sales.
(AUY) Yamana Gold makes business combination offer for Meridian Gold.
(BVF) Biovail received a non-approval letter from the U.S. FDA for its NDA for BVF-033.
(C) Citigroup $1.24 EPS vs $1.13 estimate, Revenues $25.6 Billion vs. $24.88B est.
(CAT) Caterpillar $1.24 EPS vs $1.49 estimate.
(ERIC) Ericsson ADR’s trading down over 4% after earnings rose 12% overseas.
(MSFT) Microsoft traded down almost 1% after meeting expectations.
(OWW) Orbitz IPO priced 34 million shares at $15.00.
(GOOG) Google traded down 7% after missing EPS on higher expenses.
(PRSP) Prosperity Bancshares $0.52 EPS vs $0.52 estimate.
(RHHBY) Roche profit rose 24% overseas; named new chief for diagnostics unit.
(SLB) Schlumberger $1.02 EPS vs $0.95 estimate.
(SNDK) SanDisk trading up over 4% after beating earnings.
(SNTS) Santarus announces achievement of $5 million milestone payment under license agreement wit Schering-Plough.
(SON) Sonoco $0.56 EPS vs $0.59 estimate.
(WB) Wachovia $1.23 EPS vs $1.22 estimate.
(WHR) Whirlpool $2.00 EPS vs $1.83 estimate.

Jon C. Ogg
July 20, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: July 20, 2007 – 7:21 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , ,